Применение ритуксимаба при идиопатическом гломерулонефрите и системных заболеваниях с поражением почек (обзор литературы)
Аннотация
В данном обзоре мы представляем данные международной литературы, касающиеся обоснования, дозирования и результатов применения анти-CD20 моноклональных антител (Ритуксимаба) при хроническом гломерулонефрите с нефротическим синдромом, системной красной волчанке, АНЦА-ассоциированных васкулитах и HCV-ассоциированном криоглобулинемическом васкулите.
Об авторе
Е. В. Захарова
ГУЗ г. Москвы Городская клиническая больница имени С.П. Боткина, Кафедра нефрологии МГМСУ
Россия
Россия
Список литературы
1. Ahmed M.S., Wong C.F. Should rituximab be the rescue therapy for refractory mixed cryoglobulinemia associated with hepatitis C? // J Nephrol, 2007. Vol. 20. P. 350-356
2. Ahmed M.S., Wong C.F. Rituximab and nephritic syndrome: a new therapeutic hope? // NDT, 2008. Vol. 23. P. 11-17
3. Bagga A., Sinha A., Moudgil A. Rituximab in patients with the steroid-resistant nephrotic syndrome // N Engl J Med, 2007. Vol. 356. P. 2751-2752
4. Benz K., Dotsch J., Rascher W. et al. Change of course of steroid-dependent nephrotic syndrome after rituximab therapy // Pediatr Nephrol, 2004. Vol. 19. P. 794-797
5. Bosch X. Rituximab in ANCA vasculitis: bittersweet results // Nature reviews, 2010. Vol. 6. P. 137-139
6. Cacoub P., Delluc A., Saadon D. et al. Anti-CD20 monoclonal antibody (rituximab) treatment for cryoglobulinemic vasculitis: where do we stand? // Ann Rheum Dis, 2008. Vol. 67. P. 283-287
7. E.D. Charles, L.D. Dustin. Hepatitis C virus-induced cryoglobulinemia // Kidney Int, 2009. Vol. 76. P. 818-824
8. Cobo M., Hernandez D., Rodriguez C. et al. Successful therapeutic use of rituximab in refractory membranous glomerulonephritis // Clin Nephrol, 2006. Vol. 66. P. 54-57
9. Favas C., Isenberg D.A. B-cell depletion therapy in SLE – what are current prospects for its acceptance? // Nat Rev Rheumatol, 2009. Vol. 5. P. 711-2009
10. Ferrario A.J., Smith S.W., Neil D. et al. Relapsed Wegener’s granulomatosis after rituximab therapy-B cells are present in new pathological lesions despite persistent “depletion” of peripheral blood // NDT, 2008. Vol. 23. P. 3030-3032
11. Fervenza F.C., Cosio F.G., Erickson S.B. et al. Rituximab treatment in idiopathic membranous nephropathy // Kidney Int, 2008. Vol. 73. P. 117-125
12. Francois H., Daugas E., Bensman A. et al. Unexpected efficacy of rituximab in multirelapsing minimal change nephrotic syndrome in adult; first case report and pathophysiological considerations // Am J kidney Dis, 2007. Vol. 49. P. 158-161
13. Furie R. et al. Efficacy and safety of rituximab in subjects with active proliferative lupus nephritis (LN): results of randomized, double-blind phase III LUNAR study // Arthritis Rheum, 2009 [online]
14. Furie R. et al. Effect of rituximab (RTX) on anti-dsDNA and C3 levels and relationship to response: results from the LUNAR trial // Arthritis Rheum, 2009 [online]
15. Gilbert R.D., Hulse E., Rigden S. Rituximab therapy for steroid-dependent minimal change nephritic syndrome // Pediatr Nephrol, 2006. Vol. 21. P. 1698-1700
16. Hofstra J.M., Deegens J.K., Wetzels J.F. Rituximab: effective treatment for severe steroid-dependent minimal-change nephrotic syndrome? // NDT, 2007. Vol. 22. P. 2100-2102
17. Lovric S., Erdbruegger U., Kumpers P. et al. Rituximab as rescue therapy in anti-neutrophil cytoplasmic antibody-associated vasculitis: a single-center experience with 15 patients // NDT, 2009. Vol. 24. P. 179-185
18. Merrill J.T. et al. Flare assessment in systemic lupus erythematosus (SLE) patients treated with rituximab in phase II/III EXPLORER trial // Arthritis Rheum, 2009 [online]
19. Merrill J.T. et al. Treatment of systemic lupus erythematosus (SLE) with rituximab: 78 week safety data from phase II/III EXPLORER trial // Arthritis Rheum, 2009 [online]
20. Nellessen C.M., Poge U., Brensing K.A. et al. Diffuse alveolar hemorrhage in systemic lupus erythematosus patient successfully treated with rituximab: a case report // NDT, 2008. Vol. 23. P. 385-386
21. Remuzzi G., Chiurchiu C., Abbate V. et al. Rituximab for idiopathic membranous nephropathy // Lancet, 2002. Vol. 360. P. 923-924
22. Rossi P., Demoux A.L., Granel B. et al. Anti-CD20 monoclonal antibody or treatment of refractory autoimmune haemolytic anemia associated with idiopathic membranous nephropathy // Rheumatology (Oxford), 2005. Vol. 44. P. 403-405
23. Ruggenenti P., Chiurchiu C., Brusegan V. et al. Rituximab in idiopathic membranous nephropathy: a one-year prospective study // Am J Soc Nephrol, 2003. Vol. 14. P. 1851-1857
24. Saadoun D., Rosenzwaig M., Landau D. et al. Restoration of peripheral immune homeostasis after rituximab in mixed cryoglobulinemia vasculitis // Blood, 2008. Vol. 111. P. 5334-5341
25. Saadoun D., Rigon M.R., Sene D. et al. Rituximab Plus Peg-Interferon-alpha/Ribaverin Compared with Peg-Interferon-alpha/Ribaverin in Hepatitis C-Related Mixed Cryoglobulinemia // Blood, 2010. Vol. 116. P 326-354
26. Sansonno D., De RE V., Lauetta G. et al. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with anti-CD20 // Blood, 2003. Vol. 101. P. 3818-3826
27. Sanz I., Lee F.E. B Cells as Therapeutic Targets in SLE // Nat Rev Rheumatol, 2010. Vol. 6. P. 326-337
28. Sfikakis P.P., Boletis J.N., Lionaki S. et al. Remission of proliferative lupus nephritis following B-cell depletion therapy is preceded by down-regulation of the T cell co-stimulatory molecule CD40 ligand: an open-label trial // Arthritis Rheum, 2005. Vol. 52. P. 501-513
29. Smith G.C. Is there a role of rituximab in the treatment of idiopathic childhood nephrotic syndrome? // Pediatr nephrol, 2007. Vol. 22. P. 893-898
30. Stone J.H. et al. Rituximab versus cyclophosphamide for induction remission in ANCA-associated vasculitis: a randomized controlled trial (RAVE) // Arthritis Rheum, 2009 [online]
31. Vigna-Perez M., Hemandez-Castro B., Paredes-Saharopulos O. et al. Clinical and immunological effects of rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study // Arthritis Res Ther, 2006. Vol. 8: R83
32. M. Walsh, D. Jayne. Rituximab in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis and systemic lupus erythematosus: past, present and future // Kidney Int, 2007. Vol. 72. P. 676—682
33. Yang T., Nast C.C., Vo A. et al. Rapid remission of steroid and mycofenolate mofetil (mmf)-resistant minimal change nephritic syndrome after rituximab therapy // NDT, 2008. Vol. 23. P. 377-380
Рецензия
Для цитирования:
Захарова Е.В. Применение ритуксимаба при идиопатическом гломерулонефрите и системных заболеваниях с поражением почек (обзор литературы). Нефрология и диализ. 2010;12(3):174-178.
For citation:
Zakharova E.V. Rituximab in treatment of idiopathic glomerulonephritis and systemic diseases affecting kidneys (review). Nephrology and Dialysis. 2010;12(3):174-178. (In Russ.)
Просмотров:
4
Послать статью по эл. почте 